Help your patients stay active and heart-healthy for American Heart Month with these top 5 cardio apps.
Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial
Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types
Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.
Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.
Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose
Your daily dose of the clinical news you may have missed.
Strong Link Between Increasing Lp(a) Level and Recurrent ASCVD Events Makes Screening Essential, Investigator Warns
A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.